TUDCA: Bile Acid for Mitochondrial & Cellular Stress Support

What is TUDCA?

TUDCA (tauroursodeoxycholic acid) is a secondary bile acid formed in the liver through the conjugation of ursodeoxycholic acid (UDCA) with the amino acid taurine. Bile acids are biological detergents that facilitate fat digestion and absorption in the small intestine, and they also function as signaling molecules that interact with nuclear and G-protein-coupled receptors throughout the body.

TUDCA exists naturally in small quantities in human bile and the intestinal tract, where it is produced endogenously via bacterial metabolism and hepatic conjugation. The taurine moiety enhances water solubility and bioavailability compared to unconjugated UDCA. Supplemental TUDCA is typically synthesized chemically or derived from animal bile sources, and it is absorbed in the ileum and proximal colon via specific transporters.

At the cellular level, TUDCA is studied primarily for its ability to reduce endoplasmic reticulum (ER) stress—a state of protein misfolding and cellular distress—and to stabilize mitochondrial membrane integrity. This cytoprotective effect is thought to occur partly through activation of farnesoid X receptor (FXR) and TGR5 signaling pathways, which regulate inflammatory and metabolic responses.

Evidence-based benefits of TUDCA

TUDCA is investigated in preclinical and early clinical research for several potential benefits related to cellular stress resilience and metabolic health. Most evidence to date comes from cell and animal models; human RCTs are limited outside of specialized medical contexts like cholestasis and certain neurodegenerative conditions.

Endoplasmic Reticulum Stress Reduction

In cell and animal models, TUDCA has been shown to reduce ER stress markers and attenuate the unfolded protein response (UPR). Preliminary evidence suggests this mechanism may be relevant to aging-related conditions and protein-misfolding diseases, though no robust human trials have directly measured ER stress reduction in healthy adults.

Mitochondrial Function & Bioenergetics

Preclinical studies indicate TUDCA may support mitochondrial membrane stability and ATP production capacity. A small number of in vitro and rodent studies suggest improved oxygen consumption rates and reduced reactive oxygen species (ROS) generation, but human evidence on mitochondrial bioenergetics is lacking.

Liver Health & Bile Acid Metabolism

TUDCA has established clinical use in treating intrahepatic cholestasis (excess bile acids in the liver), where it can improve bile flow and reduce liver enzyme elevation. Outside of pathological settings, small observational data suggest it may support general liver metabolic function, though large-scale preventive trials have not been conducted in healthy populations.

Neuroprotection & Neuroinflammation

Animal models and a small number of human studies in neurodegenerative diseases (e.g., Parkinson's disease) show that TUDCA may reduce neuroinflammation and support neuronal survival through ER stress reduction and mitochondrial support. Evidence is preliminary and not established in cognitively healthy individuals.

Glucose Metabolism & Insulin Sensitivity

Preclinical evidence suggests TUDCA may improve insulin sensitivity and glucose homeostasis via FXR and TGR5 signaling. Human metabolic studies are sparse; any benefit in non-diabetic populations remains speculative.

Supplement forms of TUDCA, compared

TUDCA is commercially available in a single primary form: purified tauroursodeoxycholic acid, typically supplied as a capsule or powder with no major structural variants in the supplement market.

How much TUDCA should you take?

Effective dosing of TUDCA for general health and longevity purposes has not been rigorously established in human studies. Clinical trials in cholestatic liver disease have employed doses ranging from 250 mg to 1500 mg per day, divided into 2–3 doses. Longevity-focused users often cite anecdotal or preclinical dose ranges of 250–1000 mg daily, but no evidence-based RDA or upper limit (UL) exists for otherwise healthy individuals.

• Typical longevity dose range: 250–1000 mg daily, divided into 2–3 doses
• Cholestasis clinical dose: 250–1500 mg daily in divided doses (medical supervision recommended)
• Onset of effect: Unknown in humans; animal studies suggest weeks to months for maximal benefit
• Duration: Long-term safety beyond 12 months in healthy adults is not well documented

TUDCA is typically taken with food to enhance absorption and may be divided into 2–3 doses throughout the day. Some practitioners recommend cycling (e.g., 5 days on, 2 days off) to prevent tolerance, though this practice is not validated. Avoid stacking with other bile acid supplements or high-dose antioxidants without guidance from a clinician, as synergistic effects are not well characterized.

Safety, side effects, and risks

TUDCA is generally considered well-tolerated at clinical dosages used in liver disease, with a favorable safety profile in short-term studies. However, long-term safety data in healthy, non-cholestatic individuals is sparse. As a bile acid, TUDCA carries theoretical risks related to altered bile metabolism and lipid absorption if used long-term at high doses.

Common Side Effects

Mild gastrointestinal symptoms—including loose stools, diarrhea, abdominal discomfort, and nausea—have been reported in some users, particularly at higher doses. These effects are consistent with increased bile flow and are generally dose-dependent and reversible upon discontinuation.

Serious Risks (Rare)

Severe diarrhea or electrolyte loss is theoretically possible with chronic high-dose use. Bile acid supplementation may increase risk of gallstone formation in susceptible individuals, and long-term effects on the microbiome and enterohepatic circulation are not well mapped in humans.

Pregnancy & Lactation

No adequate safety data exist for TUDCA use during pregnancy or breastfeeding. TUDCA should be avoided in these populations unless specifically prescribed by an obstetrician.

Medical Conditions

Talk to a clinician if you have a history of liver disease (including hepatitis or cirrhosis), biliary obstruction, gallstones, inflammatory bowel disease, or severe malabsorption. TUDCA is contraindicated in complete biliary obstruction and should be used with caution in patients with diarrheal disorders.

Drug and nutrient interactions

• Fat-soluble vitamins (A, D, E, K): TUDCA alters bile acid composition and may affect the absorption of fat-soluble vitamins; monitor status and consider supplementing separately if needed.
• Cholesterol-lowering drugs (statins, ezetimibe): Bile acid metabolites may interact with hepatic statin metabolism; consult your doctor before combining.
• Corticosteroids: Both TUDCA and corticosteroids influence hepatic metabolism; concurrent use warrants medical supervision.
• Antibiotics (especially broad-spectrum): Antibiotics disrupt the microbiome and alter bile acid deconjugation; timing and selection should be coordinated with your clinician.
• Other bile acid supplements (e.g., UDCA, chenodeoxycholic acid): Combining bile acids may overwhelm hepatic regulation; avoid co-supplementation without medical guidance.
• High-dose antioxidant supplements: Preclinical data suggest potential synergy with ER stress reduction, but long-term combined use is not validated in humans.

For a personalized assessment of your medications and supplements, use our supplement–drug interaction checker.

Who might benefit — and who shouldn't self-supplement without guidance

Frequently asked questions

Related ingredients